Opus Genetics is developing a gene therapy to treat ultra-rare retinal degenerative diseases.
Employment range in NC
Primary site activity
All company activities
Products under development
Opus’ lead programs focus on treatments delivered subretinally to address mutations in genes that cause different forms of Leber congenital amaurosis (LCA): OPGx-001, OPGx-002, OPGx-003